Home Shop COAs Contact Shop All →
JP Labs · Regulatory Peptide Research · Research Peptide

BPC-157 + TB500

Dual-action recovery combination. BPC-157 targets localized tissue repair while TB-500 works systemically to reduce inflammation and accelerate regeneration.

99%+ Purity Third-Party Tested US-Based Free Shipping COA Available
Shop All →
99%+ Purity Lab Certified
US-Based Fast Dispatch
Discreet Plain Packaging
Free Shipping All Orders
COA Available on Request

About BPC-157 + TB500

BPC-157 (Body Protective Compound 157) is a 15-amino acid peptide derived from a portion of Body Protective Compound found in human gastric juice. TB-500 is the synthetic form of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found throughout the body with particularly high concentrations in platelets and wound fluid. The combination provides complementary recovery mechanisms in a single vial.

BPC-157 research has demonstrated localized effects including promotion of angiogenesis (new blood vessel formation), upregulation of growth factor receptors, and modulation of nitric oxide synthesis. It has been studied for accelerating healing of tendons, ligaments, muscle, and gut tissue in animal models. TB-500 operates through a different mechanism — it binds to actin (a key structural protein in cells) and is believed to promote cell migration, proliferation, and differentiation. Its systemic distribution is broader than BPC-157, which is why the combination is of research interest for complementary localized and systemic tissue repair mechanisms.

Go Deeper
For a full breakdown of BPC-157's mechanism of action, research applications, and the BPC-157 + TB-500 combination rationale, see our BPC-157 Research Guide.
Purity
≥99%
HPLC-UV verified
Identity
LC-MS Confirmed
Mass spectrometry
Form
Lyophilized Powder
Supplied lyophilized
Storage
Lyophilized: Room temp or 2–8°C
After preparation: 2–8°C
Available Sizes
20mg
Lyophilized powder · 99%+ purity
$70

Research Applications

BPC-157 + TB500 is used in research investigating tissue repair mechanisms, tendon and ligament healing, muscle recovery, angiogenesis, anti-inflammatory pathways, and gut mucosal protection. The combination is of particular interest in studies comparing localized (BPC-157) vs. systemic (TB-500) healing mechanisms and their potential synergistic effects.

For research use only. All products sold by JP Labs are intended strictly for in vitro laboratory research. Not for human or veterinary use. Not FDA approved for any therapeutic purpose.

Common Questions

What is BPC-157?
BPC-157 (Body Protective Compound 157) is a 15-amino acid synthetic peptide derived from a protein found in human gastric juice. It has been studied extensively in rodent models for tissue repair, including tendons, ligaments, muscle, and gastrointestinal tissue.
What is TB-500?
TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a 43-amino acid peptide that occurs naturally in the body. It is believed to promote cell migration and differentiation, and has been studied for systemic healing and anti-inflammatory effects.
Why combine BPC-157 and TB-500?
BPC-157 is believed to act more locally at the site of injury through angiogenesis and growth factor receptor upregulation. TB-500 has broader systemic distribution and different cellular targets. Research interest in the combination centers on potentially complementary local and systemic repair mechanisms.

Related Compounds

Related Research

Continue Reading

Compound Comparison
BPC-157 vs Ipamorelin →
Research Article
BPC-157, Ipamorelin & Sermorelin: Mechanisms Compared →
Regulatory Notice

None of the statements on this website have been reviewed or approved by the U.S. Food and Drug Administration. JP Labs products are not intended to diagnose, treat, cure, or prevent any disease or medical condition. All products are sold strictly for in vitro laboratory research purposes. They are not for human or animal use of any kind. DiPerna Services, LLC d/b/a JP Labs is not a compounding pharmacy or outsourcing facility as defined under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.